Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2233

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 2233
---
 disrupt
our operations, and have a material and adverse effect on our business, financial condition, results of operations and prospects. If
a natural disaster, power outage, fire or other event occurred that prevented us from using all or a significant portion of our critical
infrastructure, such as our research facilities or the research or manufacturing facilities of our third-party collaborators, or that
otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial
period of time.

Our
disaster recovery and business continuity plans may prove inadequate in the event of a serious disaster or similar event. We may incur
substantial expenses as a result of the limited nature of our disaster recovery, insurance coverage, and business continuity plans, which
could have a material adverse effect on our business.

106

Risks
Related to Growing Our Organization

We
may encounter difficulties in managing our growth, which could adversely affect our operations.

As
our clinical development and commercialization plans and strategies develop, and as we transition into operating as a public company,
we will need to expand our managerial, clinical, regulatory, sales, marketing, financial, development, manufacturing and legal capabilities
or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage
additional relationships with various strategic collaborators, suppliers and other third parties. Our future growth would impose significant
added responsibilities on members of management, including:

    ●
    identifying,
    recruiting, integrating, maintaining and motivating additional employees;

    ●
    managing
    our development and commercialization efforts effectively, including the clinical and FDA review process for our product candidates,
    while complying with our contractual obligations to contractors and other third parties; and

    ●
    improving
    our operational, financial and management controls, reporting systems and procedures.

Our
ability to continue to develop and, if approved, commercialize our product candidates will depend, in part, on our ability to effectively
manage any future growth. Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities
in order to devote a substantial amount of time to managing these growth activities.

We
currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors
and consultants to provide certain services, including contract manufacturers and companies focused on research and development and discovery
activities. There can be no assurance that the services of independent organizations, advisors and consultants will